New Approach of Anti-VEGF Agents for Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is the leading cause of visual loss in older population. Angiogenesis is an important factor associated with the development of CNV due to AMD. Treatment of CNV with intravitreal anti-VEGF monotherapy is currently the standard of care. However, not all patients...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2012-01-01
|
Series: | Journal of Ophthalmology |
Online Access: | http://dx.doi.org/10.1155/2012/637316 |
id |
doaj-6decbf5a13a34ce69ecad3ac9579f63d |
---|---|
record_format |
Article |
spelling |
doaj-6decbf5a13a34ce69ecad3ac9579f63d2020-11-24T22:30:43ZengHindawi LimitedJournal of Ophthalmology2090-004X2090-00582012-01-01201210.1155/2012/637316637316New Approach of Anti-VEGF Agents for Age-Related Macular DegenerationYoung Gun Park0Hyun Wook Rhu1Seungbum Kang2Young Jung Roh3Department of Ophthalmology, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, No. 62 Yeouido-dong, Yeongdeungpo-gu, Seoul 150-713, Republic of KoreaDepartment of Ophthalmology, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, No. 62 Yeouido-dong, Yeongdeungpo-gu, Seoul 150-713, Republic of KoreaDepartment of Ophthalmology, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, No. 62 Yeouido-dong, Yeongdeungpo-gu, Seoul 150-713, Republic of KoreaDepartment of Ophthalmology, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, No. 62 Yeouido-dong, Yeongdeungpo-gu, Seoul 150-713, Republic of KoreaAge-related macular degeneration (AMD) is the leading cause of visual loss in older population. Angiogenesis is an important factor associated with the development of CNV due to AMD. Treatment of CNV with intravitreal anti-VEGF monotherapy is currently the standard of care. However, not all patients respond to monotherapy, and modified anti-VEGF treatment regimen and combination therapy may target reducing treatment frequency or improving visual outcome. This paper reviews the many clinical trials that have been performed utilizing several treatment regimens. While many trials have shown that this variable therapy is justifiable, further study is required to determine correct regimens and dosage.http://dx.doi.org/10.1155/2012/637316 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Young Gun Park Hyun Wook Rhu Seungbum Kang Young Jung Roh |
spellingShingle |
Young Gun Park Hyun Wook Rhu Seungbum Kang Young Jung Roh New Approach of Anti-VEGF Agents for Age-Related Macular Degeneration Journal of Ophthalmology |
author_facet |
Young Gun Park Hyun Wook Rhu Seungbum Kang Young Jung Roh |
author_sort |
Young Gun Park |
title |
New Approach of Anti-VEGF Agents for Age-Related Macular Degeneration |
title_short |
New Approach of Anti-VEGF Agents for Age-Related Macular Degeneration |
title_full |
New Approach of Anti-VEGF Agents for Age-Related Macular Degeneration |
title_fullStr |
New Approach of Anti-VEGF Agents for Age-Related Macular Degeneration |
title_full_unstemmed |
New Approach of Anti-VEGF Agents for Age-Related Macular Degeneration |
title_sort |
new approach of anti-vegf agents for age-related macular degeneration |
publisher |
Hindawi Limited |
series |
Journal of Ophthalmology |
issn |
2090-004X 2090-0058 |
publishDate |
2012-01-01 |
description |
Age-related macular degeneration (AMD) is the leading cause of visual loss in older population. Angiogenesis is an important factor associated with the development of CNV due to AMD. Treatment of CNV with intravitreal anti-VEGF monotherapy is currently the standard of care. However, not all patients respond to monotherapy, and modified anti-VEGF treatment regimen and combination therapy may target reducing treatment frequency or improving visual outcome. This paper reviews the many clinical trials that have been performed utilizing several treatment regimens. While many trials have shown that this variable therapy is justifiable, further study is required to determine correct regimens and dosage. |
url |
http://dx.doi.org/10.1155/2012/637316 |
work_keys_str_mv |
AT younggunpark newapproachofantivegfagentsforagerelatedmaculardegeneration AT hyunwookrhu newapproachofantivegfagentsforagerelatedmaculardegeneration AT seungbumkang newapproachofantivegfagentsforagerelatedmaculardegeneration AT youngjungroh newapproachofantivegfagentsforagerelatedmaculardegeneration |
_version_ |
1725739660256215040 |